We are live on ! Find out more
NBRV

Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV

Delisted

NBRV was delisted on the 31st of July, 2023.

Back to rankings

49 hedge funds and large institutions have $16.4M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

949% more call options, than puts

Call options by funds: $1.04M | Put options by funds: $99K

50% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 8

8% less funds holding

Funds holding: 53 → 49 (-4)

24% less capital invested

Capital invested by funds: $21.7M → $16.4M (-$5.27M)

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

Holders
49
Holders Change
-4
Holders Change %
-7.55%
% of All Funds
0.99%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
12
Reduced
8
Closed
12
Calls
$1.04M
Puts
$99K
Net Calls
+$940K
Net Calls Change
-$96K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$179K
2
WG
Winton Group
United Kingdom
+$178K
3
IWC
Integrated Wealth Concepts
Massachusetts
+$84.1K
4
PPA
Parametric Portfolio Associates
Washington
+$74.5K
5
Wells Fargo
Wells Fargo
California
+$51K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$1.34M
2
CCFM
Clear Creek Financial Management
Washington
-$195K
3
Citadel Advisors
Citadel Advisors
Florida
-$150K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$123K
5
SAMH
Shanda Asset Management Holdings
British Virgin Islands
-$103K
Name Holding Trade Value Shares
Change 		Change in
Stake
OSAM
26
O'Shaughnessy Asset Management
Connecticut
$20K +$25.4K +152 New
RWM
27
Ritholtz Wealth Management
New York
$20K +$25.4K +152 New
Citadel Advisors
28
Citadel Advisors
Florida
$16K -$150K -899 -88%
SIAP
29
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$16K – – –
Renaissance Technologies
30
Renaissance Technologies
New York
$16K +$20.4K +122 New
Deutsche Bank
31
Deutsche Bank
Germany
$14K +$17.7K +106 New
BF
32
BOK Financial
Oklahoma
$13K +$6.69K +40 +67%
WS
33
Wedbush Securities
California
$11K – – –
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
$9K -$46.8K -280 -80%
GF
35
Gabelli Funds
New York
$9K – – –
AFA
36
American Financial Advisors
Georgia
$6K – – –
First Manhattan
37
First Manhattan
New York
$6K – – –
BB
38
Bell Bank
North Dakota
$5K – – –
BG
39
Bollard Group
Massachusetts
$5K – – –
LPL Financial
40
LPL Financial
California
$5K – – –
SPIA
41
Steward Partners Investment Advisory
New York
$5K – – –
Osaic Holdings
42
Osaic Holdings
Arizona
$3K – – –
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
$3K – – –
CHAM
44
Clear Harbor Asset Management
Connecticut
$1.07K +$1.34K +8 New
CFD
45
Creative Financial Designs
Indiana
$1K -$8.69K -52 -83%
RE
46
RBC Europe
United Kingdom
$533 – – –
Millennium Management
47
Millennium Management
New York
$20 +$25.6K +153 New
CCFM
48
Clear Creek Financial Management
Washington
– -$195K -1,160 Closed
SAMH
49
Shanda Asset Management Holdings
British Virgin Islands
– -$103K -608 Closed
VF
50
Virtu Financial
New York
– -$42K -248 Closed
1
2
3

NBRV Hedge Fund Activity: Q3 2020 in Review

49 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q3 2020, worth a combined $16.4M — down 24% from $21.7M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of NBRV and 8 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 12 added.

The largest buyer was Sabby Management, opening a new position worth an estimated $179K. The largest seller was OrbiMed, cutting an estimated $1.34M.

  • 49 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q3 2020, down from 53 in Q2 2020.
  • Funds reported $16.4M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q3 2020, down 24% quarter-over-quarter.
  • 8 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q3 2020 and 12 closed out, a net change of -4 holders.
  • The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q3 2020 was Sabby Management, an estimated $179K added.
  • The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q3 2020 was OrbiMed, an estimated $1.34M sold.

Based on aggregated 13F filings for Q3 2020.